An interventional study of Harmony and National Institute on Aging Program in Dementia Alzheimers and Alzheimer Disease, sponsored by Elizabeth K Rhodus. Completed at 1 site in United States. Open to participants aged 21 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Elizabeth K Rhodus · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 737th largest by enrollment of the 1,610 interventional ones that give a count, is one of 115 that started in 2023, is one of 610 with no phase, and was the 1,551st registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 21 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,941 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 115 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,610 interventional studies, 160 across the 309 observational. Of the 1,379 that completed or were terminated, 592 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,941 have an industry lead sponsor. The 10 most frequent:
Elizabeth K Rhodus is the lead sponsor of 4 studies on the registry; none are open to participants now.
Elizabeth K Rhodus has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,941 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial will assess feasibility of a non-pharmacological intervention for persons living with Alzheimer's disease and related dementias (ADRD) to improve behavioral and psychiatric symptoms of dementia and functional performance.
Using a two-arm, prospective randomized controlled trial, 38 dyads (person with ADRD and caregiver) will complete an 8-week telehealth occupational therapy intervention provided via Zoom with caregivers and persons with dementia or receive an active control with 8 telehealth sessions to discuss publicly available caregiver education with a non-clinical research assistant.
Inclusion Criteria: Participants with Dementia
Inclusion Criteria: Caregiver for Participants with Dementia
Exclusion Criteria: Participants with Dementia
Exclusion Criteria: Caregiver for Participant with Dementia:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive the Harmony intervention.
Behavioral: Harmony
Participants in this group will receive the National Institute on Aging education.
Behavioral: National Institute on Aging Program
The Harmony intervention builds on prior successful foundations of dementia care interventions with a novel approach combining remote implementation, antecedent education, and home environment intervention. The intervention will teach caregivers how to 1) assess the home environment as an antecedent to behavior for the person with ADRD, and 2) design and implement individualized environmental modification through an environmental cueing approach to address the needs of the person with ADRD in a supportive environment.
Standard of care will address behaviors and psychiatric symptoms of dementia (BPSD) for persons with ADRD, as recommended by their medical provider. Caregivers will receive training regarding home safety via a home safety handout based on National Institutes on Aging "Home Safety and Alzheimer's Disease" webpage.
Change in Patient Performance as Measured by Canadian Occupational Performance Measure (COPM)
Criterion-referenced interview of patient performance with caregiver The COPM is a reliable and validated measure of performance in primary daily activities (self-care, leisure, productivity) with dyad-caregiver rated of performance and satisfaction. Scores are determined on a likert scale of 1-10 with 1 being lowest and 10 indicating highest of the topic of the question.
Time frame: Baseline to 13 Week Follow-Up
Caregiver Satisfaction of Patient Performance [Feasibility]
The primary outcome analysis is the feasibility of implementation as measured by caregiver satisfaction. The Canadian Occupational Performance Measure will measure caregiver satisfaction of patient performance, high scores indicate higher levels of satisfaction. Range 0-10.
Time frame: Baseline to 13 Week Follow-Up
Zarit Caregiver Burden Scale
22-item survey, caregiver rates self-perceived level of burden on 5-point Likert scale. The social context of the person with ADRD will be described through analysis of caregiver demographics and rate of caregiver burden measured. Higher scores indicate greater burden. Range of 0-88 points. A score of 17 or more was considered high burden.
Time frame: Baseline to 13 Week Follow-Up
Neuropsychiatric Inventory Questionnaire (NPI-Q)
The NPI-Q is commonly used as an assessment of behavioral and psychiatric symptoms of dementia in older adults diagnosed with mild cognitive impairment or dementia, internationally, with high reliability and validity. Assessment includes 12 behavioral and psychiatric domains which are rated by caregiver as present or absent (yes/no). Caregivers further rate severity of present behavioral domains. The severity score is summed to yield a total as a measure of BPSD burden. Higher scores indicate higher levels of behavior symptom severity and/or distress. Range 0-36
Time frame: Baseline to 13 Week Follow-Up
Functional Behavior Profile (FBP)
Criterion-referenced survey completed by caregiver. The FBP has been established as a reliable and valid measure of task performance, social interaction, and problem solving with adults with ADRD. The FBP consists of 27 items rated from 0 to 4, with higher scores indicating better performance. The total score ranges from 0 to 108. The FBP includes three subscales: Task Performance (0-36), Social Interaction (0-24) and Problem Solving (0-48). Subscale scores are summed to calculate the total FBP score.
Time frame: Baseline to 13 Week Follow-Up
| Milestone | Harmony | National Institute on Aging Program |
|---|---|---|
| Started | 38 | 38 |
| Completed | 34 | 32 |
| Not completed | 4 | 6 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Adverse event | 0 | 4 |
Criterion-referenced interview of patient performance with caregiver The COPM is a reliable and validated measure of performance in primary daily activities (self-care, leisure, productivity) with dyad-caregiver rated of performance and satisfaction. Scores are determined on a likert scale of 1-10 with 1 being lowest and 10 indicating highest of the topic of the question.
| score on a scale | Harmony | National Institute on Aging Program |
|---|---|---|
| Change in Patient Performance as Measured by Canadian Occupational Performance Measure (COPM) | 1.14 ± 2.21 | -0.37 ± 2.3 |
The primary outcome analysis is the feasibility of implementation as measured by caregiver satisfaction. The Canadian Occupational Performance Measure will measure caregiver satisfaction of patient performance, high scores indicate higher levels of satisfaction. Range 0-10.
| score on a scale | Harmony | National Institute on Aging Program |
|---|---|---|
| Caregiver Satisfaction of Patient Performance [Feasibility] | 2.34 ± 2.76 | 0.72 ± 1.86 |
22-item survey, caregiver rates self-perceived level of burden on 5-point Likert scale. The social context of the person with ADRD will be described through analysis of caregiver demographics and rate of caregiver burden measured. Higher scores indicate greater burden. Range of 0-88 points. A score of 17 or more was considered high burden.
| score on a scale | Harmony | National Institute on Aging Program |
|---|---|---|
| Zarit Caregiver Burden Scale | -0.84 ± 8.54 | -5.29 ± 6.22 |
The NPI-Q is commonly used as an assessment of behavioral and psychiatric symptoms of dementia in older adults diagnosed with mild cognitive impairment or dementia, internationally, with high reliability and validity. Assessment includes 12 behavioral and psychiatric domains which are rated by caregiver as present or absent (yes/no). Caregivers further rate severity of present behavioral domains. The severity score is summed to yield a total as a measure of BPSD burden. Higher scores indicate higher levels of behavior symptom severity and/or distress. Range 0-36
| score on a scale | Harmony | National Institute on Aging Program |
|---|---|---|
| Neuropsychiatric Inventory Questionnaire (NPI-Q) | -0.81 ± 1.69 | 0.38 ± 1.59 |
Criterion-referenced survey completed by caregiver. The FBP has been established as a reliable and valid measure of task performance, social interaction, and problem solving with adults with ADRD. The FBP consists of 27 items rated from 0 to 4, with higher scores indicating better performance. The total score ranges from 0 to 108. The FBP includes three subscales: Task Performance (0-36), Social Interaction (0-24) and Problem Solving (0-48). Subscale scores are summed to calculate the total FBP score.
| score on a scale | Harmony | National Institute on Aging Program |
|---|---|---|
| Functional Behavior Profile (FBP) | 6.16 ± 10.66 | -1.23 ± 7.42 |
Collected over 13 Weeks (Initial baseline through the 4 week follow up). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Harmony | 0/38 (0%) | 0/38 (0%) | 9/38 (23.7%) |
| National Institute on Aging Program | 0/38 (0%) | 2/38 (5.3%) | 3/38 (7.9%) |
| Event | Harmony | National Institute on Aging Program |
|---|---|---|
| Transient Ischemic AttackNervous system disorders | 0/38 | 1/38 |
| Psychiatric Change Resulting in HospitalizationPsychiatric disorders | 0/38 | 1/38 |
| Event | Harmony | National Institute on Aging Program |
|---|---|---|
| FallInjury, poisoning and procedural complications | 9/38 | 1/38 |
| Fungal Skin InfectionInfections and infestations | 0/38 | 1/38 |
| Transient Ischemic AttackNervous system disorders | 0/38 | 1/38 |
| Age, Continuous(years) | Harmony | National Institute on Aging Program | Total |
|---|---|---|---|
| ADRD | 77.53 ± 9.930 | 79.61 ± 10.279 | 77.93 ± 9.996 |
| Caregivers | 66.83 ± 10.183 | 60.47 ± 11.271 | 63.15 ± 10.809 |
| Sex: Female, Male(Participants) | Harmony | National Institute on Aging Program | Total |
|---|---|---|---|
| ADRD — Female | 15 | 10 | 25 |
| ADRD — Male | 4 | 8 | 12 |
| Caregivers — Female | 12 | 17 | 29 |
| Caregivers — Male | 7 | 2 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Harmony | National Institute on Aging Program | Total |
|---|---|---|---|
| ADRD — Hispanic or Latino | 4 | 1 | 5 |
| ADRD — Not Hispanic or Latino | 15 | 17 | 32 |
| ADRD — Unknown or Not Reported | 0 | 1 | 1 |
| Caregivers — Hispanic or Latino | 0 | 1 | 1 |
| Caregivers — Not Hispanic or Latino | 16 | 17 | 33 |
| Caregivers — Unknown or Not Reported | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Harmony | National Institute on Aging Program | Total |
|---|---|---|---|
| ADRD — American Indian or Alaska Native | 0 | 0 | 0 |
| ADRD — Asian | 0 | 0 | 0 |
| ADRD — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| ADRD — Black or African American | 3 | 0 | 3 |
| ADRD — White | 16 | 18 | 34 |
| ADRD — More than one race | 0 | 0 | 0 |
| ADRD — Unknown or Not Reported | 0 | 1 | 1 |
| Caregivers — American Indian or Alaska Native | 0 | 0 | 0 |
| Caregivers — Asian | 0 | 0 | 0 |
| Caregivers — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Caregivers — Black or African American | 3 | 0 | 3 |
| Caregivers — White | 16 | 19 | 35 |
| Caregivers — More than one race | 0 | 0 | 0 |
| Caregivers — Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Harmony | National Institute on Aging Program | Total |
|---|---|---|---|
| United States | 38 | 38 | 76 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in Jun 2025, 24 months.
Results were first posted in Nov 2026, 1 year 4 months after primary completion.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 24 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elizabeth K Rhodus